Scott A. Tomlins, M.D., Ph.D. is an Associate Professor of Pathology and Urology. He is an active member of the diagnostic Genitourinary Pathology service and performs translational research on incorporating protein, DNA and RNA based assays into clinical practice.

He led the development and signs out the urine-based prostate cancer early detection test (MiPS) offered through the Michigan Center for Translational Pathology (MCTP) clinical lab. He led the first exome sequencing based study of castration resistant prostate cancer and is developing broadly applicable personalized medicine approaches to prostate cancer early detection, prognosis and treatment of advanced disease. In 2013, in recognition of his work in the molecular pathology of prostate cancer, he was awarded the inaugural AAAS Martin and Rose Wachtel Cancer Research Award for Young Investigators.

Research in the Tomlins lab utilizes integrative high-throughput approaches, including next generation sequencing, to understand the molecular profile genitourinary malignancies, including clinical subtyping of prostate cancer, as well as bladder and adrenocortical carcinoma.

In addition to molecular classification, projects to functionally validate intriguing candidates from our studies and other large scale cancer sequencing projects are ongoing.

The laboratory is equipped with Ion Proton and Ion S5 Sequencers for next generation sequencing. The ABI QuantStudio 12K flex system is used for high throughput gene expression analysis.